Allogene Therapeutics Stock Price, News & Analysis (NASDAQ:ALLO)

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLO shares.
View ALLO analyst ratings or view top-rated stocks.

11 equities research analysts have issued twelve-month price objectives for Allogene Therapeutics' stock. Their ALLO share price targets range from $6.00 to $31.00. On average, they anticipate the company's stock price to reach $15.35 in the next twelve months. This suggests a possible upside of 553.0% from the stock's current price.
View analysts price targets for ALLO or view top-rated stocks among Wall Street analysts.

Allogene Therapeutics' stock was trading at $6.29 at the start of the year. Since then, ALLO shares have decreased by 62.6% and is now trading at $2.35.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our ALLO earnings forecast.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) released its earnings results on Thursday, November, 2nd. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.16. The business earned $0.04 million during the quarter, compared to analysts' expectations of $0.05 million. Allogene Therapeutics had a negative net margin of 178,954.28% and a negative trailing twelve-month return on equity of 54.03%.

ETFs with the largest weight of Allogene Therapeutics (NASDAQ:ALLO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion Moonshot Innovators ETF (MOON), Simplify Propel Opportunities ETF (SURI), Range Cancer Therapeutics ETF (CNCR), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX) and

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

(ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO.

Allogene Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (14.94%), JPMorgan Chase & Co. (4.11%), Primecap Management Co. CA (3.14%), Rafferty Asset Management LLC (0.54%), Barclays PLC (0.47%) and Charles Schwab Investment Management Inc. (0.47%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Owen N Witte, Owen N Witte, Rafael Amado, Stephen Mayo and Veer Bhavnagri.
View institutional ownership trends.

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.